Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This study tests an oral drug called LP-118 for people with a wide range of blood cancers that have come back or stopped responding to prior treatments. LP-118 targets a protein that helps blood cancer cells survive. The study covers many blood cancer types including CLL, AML, multiple myeloma, lymphomas, and others. **You may be eligible if...** - You are 18 or older (or 13–18 if you have ALL and weigh at least 40 kg) - You have a blood cancer that has relapsed or is no longer responding to treatment - You have received at least two prior treatments (for most cancer types) - Your blood counts and organ function meet the study requirements **You may NOT be eligible if...** - Your cancer is no longer classified as relapsed or refractory - You have had recent serious infections or major organ failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.